Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20873865 | 0.87 | LTA4H (0.40) | HSD11B1TSHRCA12CA1CA2 | |
| SCHEMBL11028372 | 0.80 | LTA4H (0.41) | HSD11B1ALDH1A1HTTLTA4HCYP2D6 | |
| SCHEMBL314696 | 0.79 | HSD11B1 (0.50) | HSD11B1ALDH1A1KDM4ETSHRCA12 | |
| SCHEMBL19329792 | 0.78 | SIGMAR1 (0.53) | HSD11B1ALDH1A1KDM4ETSHRCA12 | |
| SCHEMBL7429017 | 0.78 | KDM4E (0.55) | ALDH1A1KDM4ETSHRKMT2AHSD17B10 | |
| SCHEMBL14392151 | 0.78 | KEAP1 (0.47) | LTA4HCYP2D6ALOX15 | |
| Bicarbonate SCHEMBL8660627 | 0.78 | ALDH1A1 (0.54) | HSD11B1ALDH1A1KDM4ETSHRHTT | |
| SCHEMBL9186250 | 0.77 | KDM4E (0.54) | HSD11B1ALDH1A1KDM4ETSHRHTT | |
| SCHEMBL9380398 | 0.77 | F2 (0.46) | HSD11B1ALDH1A1KDM4ETSHRCA12 | |
| SCHEMBL11700336 | 0.77 | DUSP3 (0.50) | HSD11B1ALDH1A1KDM4ETSHRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283920-B | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2024-04-16 | — | — | CN | claimed |
| CN-116283920-A | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2023-06-23 | — | — | CN | claimed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | claimed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | claimed |
| EP-3498716-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | Hongyun Biotech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | claimed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| CN-116283920-B | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2024-04-16 | — | — | CN | disclosed |
| CN-116283920-A | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2023-06-23 | — | — | CN | disclosed |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | Hongyun Biotech Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| CN-109575045-B | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof | 南京红云生物科技有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | disclosed |
| WO-2006107561-A1 | TETRAHYDROTHIOPYRANO PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223798-A1 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-10-05 | — | — | US | disclosed |
| EP-1657241-A1 | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006048248-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE IMHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223798-A1 | Tetrahydrothiopyrano pyrazole cannabinoid modulators | CNR1, CNR2, GPR18 | HSD11B1 1075/4885ALDH1A1 1724/4885KDM4E 2507/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | HSD11B1 995/4885ALDH1A1 298/4885KDM4E 2494/4885 |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | HSD11B1 3966/4885ALDH1A1 616/4885KDM4E 463/4885 |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | KDR, FLT4, FLT1 | HSD11B1 4807/4885ALDH1A1 619/4885KDM4E 243/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | HSD11B1 3966/4885ALDH1A1 616/4885KDM4E 463/4885 |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | ALK, MET, TIE1 | HSD11B1 3966/4885ALDH1A1 616/4885KDM4E 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.